IDEXX Laboratories Announces First Quarter Results News provided by Share this article WESTBROOK, Maine, May 4, 2021 /PRNewswire/ -- Achieves reported revenue growth of 24% and organic growth of 21%, driven by CAG Diagnostics recurring revenue growth of 27% as reported and 23% organic Delivers EPS of $2.35, representing 82% growth as reported and 73% on a comparable basis Increases 2021 revenue guidance to $3,105 million - $3,160 million, reflecting higher expectations for reported growth of 14.5% - 16.5% and organic growth of 13% - 15%, supported by projected CAG Diagnostics recurring revenue growth of 16% - 17.5% as reported and 14.5% - 16% organic Raises 2021 EPS outlook to $7.88 - $8.18, reflecting expectations for 1.5% higher organic revenue growth and targeted operating margin improvement of 270 - 320 basis points as reported and 150 - 200 basis points on a comparable basis